Erasca: How the biotech company aims to revolutionize oncology

Erasca is a pure development company in precision oncology that currently has no products on the market and therefore generates no revenue, relying entirely on venture capital and partnerships. Despite severe share price drops in spring 2026 due to a death in an early study and a patent dispute, the stock market still values the company at over USD 5.7 billion in July 2026. The future growth depends on the success of the hopeful candidate ERAS-0015 and the strategy to block cancer cells simultaneously at multiple biological checkpoints through...